Metabolic and genetic studies of glimepiride and metformin and their association with type 2 diabetes

Despite the impact of genetic heritage on therapeutic biological responses is still poorly understood, understanding of the genetics of type 2 diabetes is increasing. Pharmacogenetics is considered as a tool to better understand the therapeutic variability of the pathology. Genetic studies based on mononucleotide polymorphisms (SNPs) certainly influence the effects of oral antidiabetics such as Biguanides (metformin) which are transported by OCT1 and OCT2 coded respectively by SLC22A1 and SLC22A2; and the sulfonamides (glimepiride) which are transported by SUR1 coded by ABCC8, the receptor Kir1.6 coded by KCNJ11 and TCF-4 which is coded by TCF7L2. This new field in Morocco requires large-scale genetic studies which will enable us to predict the results of treatment in order to individualize and improve the drug prescription by selecting the most appropriate molecule and adapting the dose administered to each patient.